Tenderwize
Retour à la recherche

Open-House Biologics Discount Contracts 2024-11 - Hepatitis B Immune Globulin (ATC Code J06BB04)

Techniker Krankenkasse·Hamburg, Germany·Deadline Oct 29, 2026 · 64 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2024-11 - Hepatitis-B-Immunglobulin (ATC-Code J06BB04)

50/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

40 / 100

Facteurs de risque

No commitment from health insurers to purchase any quantity; actual uptake depends on pharmacy selections.

Subject to dispute resolution via social courts, not procurement chambers; legal uncertainty if classification as publi...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Oct 2026
  • Conclusion of discount contracts for Hepatitis-B immune globulin (ATC J06BB04) with qualified pharmaceutical entrepreneurs
  • Open-house procedure with no exclusivity and no negotiation of terms
Afficher le résumé complet

Open-house procedure by German health insurers (Techniker Krankenkasse, HEK, hkk) to conclude discount contracts for Hepatitis-B immune globulin (ATC J06BB04) under §130a Abs. 8 SGB V. The procedure runs from 01.11.2024 to 31.10.2026, with eligibility for any qualified pharmaceutical entrepreneur meeting authorization and reliability criteria. Contracts are non-exclusive, no negotiations, and participation possible at any time during the term. No estimated value provided.

Risques

No commitment from health insurers to purchase any quantity; actual uptake depends on pharmacy selections.

Subject to dispute resolution via social courts, not procurement chambers; legal uncertainty if classification as publi...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur according to §4 Abs. 18 AMG regarding the offered medicinal product
  • Must have a valid marketing authorization under §21 AMG or equivalent right to place on the market
  • Must have seat in Germany, EU, or EEA (§9 Abs. 2 AMG)

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open-House Biologics Discount Contracts 2024-11 - Hepatitis B Immune Globulin (ATC Code J06BB04)

Conclusion of discount contracts for Hepatitis-B immune globulin (ATC J06BB04) as an open-house procedure. No exclusivity, no negotiations, uniform conditions.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Oct 2024 - Oct 2026

Catégorie

Pharmaceutical products

Date limite

Deadline Oct 29, 2026

Détails de la procédure

Date de publication
22 Sep 2024
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
569809-2024

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3